Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have received an average rating of “Moderate Buy” from the ...

We recently compiled a list of the 12 Best Telecom Stocks To Invest In Now. In this article, we are going to take a look at ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 19.50% ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

International Revenue Predictions Wall Street analysts expect Cogent to report a total revenue of $261.29 million in the current fiscal quarter, which suggests a decline of 4% from the prior-year ...

Needham downgraded Cogent Biosciences (COGT) to Hold from Buy without a price target The firm says its expert feedback on the latest feedback raises concerns on the utilization of bezuclastinib in ...

Cogent Biosciences (COGT) announced updated clinical results from the Open Label Extension OLE, portion of SUMMIT, a clinical trial evaluating ...

Cogent Communications Holdings, Inc.（纳斯达克股票代码：CCOI）的首席营收官James Bubeck于2024年12月9日出售了1,920股公司普通股。这些股票以平均价格76.60美元售出，交易总额约为147,065美元。此次交易发生时，公司股价接近52周高点86.76美元，目前公司市值为36.3亿美元。根据 InvestingPro 分析，CCOI的市盈率为 ...

Bezuclastinib is a small molecule commercialized by Cogent Biosciences, with a leading Phase III program in Gastrointestinal Stromal Tumor (GIST).

Cogent Biosciences (COGT) reported positive updated data from Part 1 of the company’s ongoing Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...